Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972738 | 0.92 | KDM4E (0.40) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL2200898 | 0.90 | TOP1 (0.37) | KDM4EALDH1A1TDP1POLBLMNA | |
| SCHEMBL12427372 | 0.86 | KCNH2 (0.47) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL13744369 | 0.85 | KDM4E (0.63) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL12427396 | 0.84 | KCNH2 (0.47) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL12427373 | 0.84 | TOP1 (0.39) | KDM4EALDH1A1KCNH2TDP1POLB | |
| SCHEMBL1973336 | 0.83 | TOP1 (0.32) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL12427329 | 0.83 | KCNH2 (0.44) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL13744782 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HPGDKCNH2TDP1 | |
| SCHEMBL13744543 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1HPGDKCNH2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-1994020-B1 | Substituted quinolones III | AICURIS GMBH & CO KG (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | IRF3, TPMT, TOP2A | KDM4E 1743/4885ALDH1A1 3228/4885HPGD 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.